
Johnson & Johnson (NYSE:JNJ) yesterday escaped a shareholders derivative lawsuit alleging that the company over-paid former CEO William Weldon, who presided over a spate of recalls that bedeviled the healthcare giant a few years back.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Johnson & Johnson (NYSE:JNJ) yesterday escaped a shareholders derivative lawsuit alleging that the company over-paid former CEO William Weldon, who presided over a spate of recalls that bedeviled the healthcare giant a few years back.
The CEO of Varian Medical (NYSE:VAR) is planning to retire from the corner office in September, to be replaced by COO Dow Wilson, according to a regulatory filing.
A significant chunk of Smith & Nephew‘s (FTSE:SN; NYSE:SNN) shareholders withheld their endorsement or voted outright against a $2.5 million "golden hello" for new CEO Olivier Bohuon after an advisory board recommended a veto.
Boston Scientific (NYSE:BSX) employees could see their annual bonus payments shrink or grow based on the device maker’s adjusted earnings per share and global sales by the end of the year, thanks to a new performance incentive plan for 2012.
The Natick, Mass.-based med-tech titan reconfigured its employee reward system, tying the total potential payout for all regions and division into a single pool, the value of which fluctuates along with the company’s performance in 2012.
Boston Scientific (NYSE:BSX) employees could see their annual bonus payments shrink or grow based on the device maker’s adjusted earnings per share and global sales by the end of the year, thanks to a new performance incentive plan for 2012.
The Natick, Mass.-based med-tech titan reconfigured its employee reward system, tying the total potential payout for all regions and division into a single pool, the value of which fluctuates along with the company’s performance in 2012.
Updated February 1, 2012 at 5:30 p.m.
The $372 million buyout of Navilyst Medical by AngioDynamics (NSDQ:ANGO) is a reset button that will reinforce the combined operation for the future, AngioDynamics CEO Joe DeVivo told MassDevice this afternoon.
Synthes CEO Michel Orsinger
Synthes CEO Michel Orsinger will land a $52 million payout to give up the corner office as part of the Swiss orthopedic device maker’s $21.3 billion buyout by med-tech titan Johnson & Johnson (NYSE:JNJ).
The deal, slated to close in early 2012, includes a $51.9 million payout to Orsinger for leaving Synthes and a multimillion-dollar stock package for his new position with Johnson & Johnson.
Bovie Medical Corp. (NYSE:BVX) is demoting COO Moshe Citronowicz and cutting his pay and benefits after determining that he misrepresented his academic career.
Citronowicz, who has been with the electrosurgery company since 1993, claimed to have a bachelor’s degree in electrical engineering from Israel’s University of Be’er Sheva, according to a regulatory filing.
Robert Parkinson Jr., chairman & CEO of Baxter International (NYSE:BAX), added 20 percent to his paycheck total from last year by cashing in on stock options for the first time.
Parkinson, 60, who earned $11.5 million last year, netted $14.1 million last month after exercising the options and selling stock.